Clinical Trials Logo

Clinical Trial Summary

The purpose of this clinical trial is to demonstrate the efficacy and safety of the Osprey Medical CINCORâ„¢ Contrast Removal System.


Clinical Trial Description

The CINCORâ„¢ Catheter System to retrieve contrast media from the coronary sinus following injection during percutaneous coronary interventions. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention


Related Conditions & MeSH terms

  • Radiographic Contrast Agent Nephropathy

NCT number NCT01168024
Study type Interventional
Source Osprey Medical, Inc
Contact
Status Terminated
Phase Phase 3
Start date December 2012
Completion date November 2013

See also
  Status Clinical Trial Phase
Completed NCT00540904 - Prevention of Contrast Induced Nephropathy in Oncology Patients With Sodium Bicarbonate Phase 2
Recruiting NCT00584350 - Prevention of Contrast Nephropathy During Diagnostic Coronary Angiogram or PCI With Hydratation Based on LEVDP Phase 4
Recruiting NCT01820195 - N-Acetyl Cystein and Contrast Nephropathy Phase 3
Completed NCT02137863 - Efficacy of Dexmedetomidine in Preventing Contrast Induced Nephropathy Phase 4
Completed NCT01866800 - The Effect of the Forced Diuresis With Matched Hydration in Reducing Acute Kidney Injury During TAVI Phase 4
Active, not recruiting NCT01778140 - Comparing Effects of Patient-specific Versus Non-patient-specific Computerized Reminder System N/A
Completed NCT02483143 - NAC, NaHCO3 and NS Prophylaxis for CTPA in the ED on Suspicion of PE: A Randomized Controlled Trial Phase 4
Completed NCT01525888 - Renin-angiotensin-aldosterone System (RAAS) Blockade and Contrast Induced Nephropathy N/A
Recruiting NCT02643706 - Relationship Between ALDH2 and CIN N/A
Completed NCT02643602 - Does Bicarbonate in Addition to Theophylline Reduce CIN? N/A
Recruiting NCT02029820 - RenalGuard System for Prevention of Contrast Induced Nephropathy Phase 3
Terminated NCT01654328 - Oral Versus Intravenous Hydration to Prevent Contrast Induced Nephropathy N/A